Enanta Pharmaceuticals (NASDAQ:ENTA) Given New $24.00 Price Target at JMP Securities

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) had its price target raised by JMP Securities from $23.00 to $24.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a "market outperform" rating on the biotechnology company's stock. JMP Securities' price target would indicate a potential upside of 237.55% from the stock's previous close.

A number of other equities research analysts have also recently issued reports on ENTA. HC Wainwright reaffirmed a "buy" rating and issued a $18.00 price objective on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 11th. Wall Street Zen upgraded shares of Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Wednesday, February 19th. One research analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Enanta Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $18.00.

Enanta Pharmaceuticals Stock Down 1.1%

NASDAQ ENTA traded down $0.08 during trading hours on Tuesday, reaching $7.11. 141,124 shares of the company were exchanged, compared to its average volume of 286,188. Enanta Pharmaceuticals has a 1 year low of $4.09 and a 1 year high of $17.24. The business's 50 day simple moving average is $5.42 and its 200-day simple moving average is $6.22. The stock has a market capitalization of $151.99 million, a P/E ratio of -1.44 and a beta of 0.81.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last posted its earnings results on Monday, May 12th. The biotechnology company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($1.04) by ($0.02). Enanta Pharmaceuticals had a negative return on equity of 75.53% and a negative net margin of 157.57%. The business had revenue of $14.93 million during the quarter, compared to analysts' expectations of $15.96 million. As a group, sell-side analysts anticipate that Enanta Pharmaceuticals will post -4.65 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ENTA. China Universal Asset Management Co. Ltd. bought a new position in Enanta Pharmaceuticals in the 4th quarter worth $26,000. US Bancorp DE bought a new position in shares of Enanta Pharmaceuticals in the 1st quarter worth about $36,000. GAMMA Investing LLC purchased a new position in Enanta Pharmaceuticals during the 1st quarter valued at about $40,000. Tower Research Capital LLC TRC lifted its position in Enanta Pharmaceuticals by 46.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company's stock valued at $41,000 after acquiring an additional 2,274 shares during the period. Finally, Intech Investment Management LLC bought a new stake in Enanta Pharmaceuticals during the fourth quarter worth about $58,000. 94.99% of the stock is currently owned by institutional investors.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.